Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03518242 | Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer | completed | Phase 1 | 100 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT01276899 | Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients | completed | — | 80 | Jewish General HospitalOTHER | 2 | Jun 2, 2022 | clinicaltrials |
| NCT02536794 | MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT01688388 | Single Fraction Intraoperative Radiotherapy | completed | N/A | 250 | St. Joseph Hospital of OrangeOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT01904903 | Cardiac Safety Study in Patients With HER2 + Breast Cancer(SAFE-HEaRt) | completed | Phase 2 | 31 | Medstar Health Research InstituteOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02698891 | Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer | completed | Phase 2 | 127 | Dana-Farber Cancer InstituteOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03254654 | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer | completed | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04498611 | Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy | completed | N/A | 113 | Seoul National University HospitalOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT04693364 | Acceptability of 3D Printed Breast Models as Surgical Decision Aids for Breast Cancer Treatment | completed | — | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03524170 | Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | completed | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT04478669 | Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer(DBT) | completed | — | 250 | Aarhus University HospitalOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT03243838 | Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer(LANCET) | completed | Phase 2 | 31 | Guangdong Provincial People's HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02297412 | Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel | completed | Phase 2 | 47 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT04866992 | Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)(SPrNSM) | completed | — | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT03281824 | Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients | completed | Phase 1 | 27 | Alteogen, Inc.INDUSTRY | 1 | Jan 18, 2022 | clinicaltrials |
| NCT03556358 | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | completed | Phase 3 | 809 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Jan 14, 2022 | clinicaltrials |
| NCT02296801 | A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer(PALLET) | completed | Phase 2 | 307 | NSABP Foundation IncNETWORK | 3 | Jan 13, 2022 | clinicaltrials |
| NCT01849250 | Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Dec 28, 2021 | clinicaltrials |
| NCT02555657 | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | completed | Phase 3 | 622 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Dec 10, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03176979 | Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer | completed | N/A | 43 | University of Southern CaliforniaOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04245657 | Factors Affecting Functionality in Breast Cancer Survivors | completed | — | 111 | Izmir Bakircay UniversityOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03834532 | Living Well After Breast Surgery | completed | N/A | 17 | University of Texas at AustinOTHER | 1 | Nov 2, 2021 | clinicaltrials |
| NCT03789877 | A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity | completed | N/A | 30 | Roswell Park Cancer InstituteOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03457779 | Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer | completed | N/A | 16 | Baylor Research InstituteOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT03931928 | Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients(TAMENDOX) | completed | Phase 2 | 356 | Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)OTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT03959267 | Testing a Culturally Adapted Telephone Genetic Counseling Intervention | completed | N/A | 37 | Georgetown UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT02227082 | Olaparib and Radiotherapy in Inoperable Breast Cancer | completed | Phase 1 | 7 | The Netherlands Cancer InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT01931163 | NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer(NECTAR) | completed | Phase 2 | 24 | Jenny C. Chang, MDOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT01448447 | Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®(Mammosite ML) | completed | N/A | 20 | Mercy ResearchOTHER | 1 | Jul 15, 2021 | clinicaltrials |
| NCT00581750 | Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ | completed | — | 550 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 2, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT01023477 | Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) | completed | Phase 1 / Phase 2 | 12 | Inova Health Care ServicesOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT03113825 | Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery | completed | Phase 2 | 92 | Avelas Biosciences, Inc.INDUSTRY | 1 | Jun 11, 2021 | clinicaltrials |
| NCT03411161 | S 81694 Plus Paclitaxel in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Institut de Recherches Internationales ServierOTHER | 4 | May 25, 2021 | clinicaltrials |
| NCT04817709 | Development of a Patient Decision Aid for Women Considering Breast Reconstruction | completed | — | 126 | M.D. Anderson Cancer CenterOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT03197389 | Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. | completed | Early Phase 1 | 54 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT00256217 | Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women | completed | Phase 2 | 42 | Rita Sanghvi, MehtaOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT02413320 | Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer(NeoSTOP) | completed | Phase 2 | 101 | Priyanka SharmaOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT04829890 | Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer | completed | — | 89 | Hellenic Cooperative Oncology GroupOTHER | 0 | Apr 6, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT03577743 | Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 54 | Assiut UniversityOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT03135782 | Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy | completed | N/A | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT02324088 | Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer(PEGASE07) | completed | Phase 3 | 174 | UNICANCEROTHER | 0 | Feb 21, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2022source: clinicaltrials